Rosuvastatin at doses of 5 to 80 mg significantly reduced mean triglyceride levels by 18% to 40% compared with a 2.9% increase with placebo (P≤0.001).
RCT (n=156)
Double-blind
parallel-group
Yes
Does rosuvastatin improve triglyceride levels and lipid profiles in patients with hypertriglyceridemia?
Rosuvastatin significantly reduces triglyceride levels and improves atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia.
p-value: p=≤ 0.001
BACKGROUND: We examined the effects of rosuvastatin treatment on triglyceride levels and lipid measures in a parallel-group multicenter trial (4522IL/0035) in patients with hypertriglyceridemia (Fredrickson Type IIb or IV). METHODS: After a 6-week dietary lead-in period while on a National Cholesterol Education Program step I diet, 156 patients with fasting triglyceride levels >/= 300 and 5 mg. The occurrence of adverse events was generally low and not dose related, although some adverse events occurred more frequently in the rosuvastatin 80 mg group. CONCLUSIONS: Rosuvastatin reduced triglyceride levels and improved the overall atherogenic and atheroprotective lipid profiles in hypertriglyceridemic patients.
Hunninghake et al. (Thu,) conducted a rct in hypertriglyceridemia (n=156). rosuvastatin vs. placebo was evaluated on mean percentage change from baseline in total serum triglyceride levels at week 6 (p=≤ 0.001). Rosuvastatin at doses of 5 to 80 mg significantly reduced mean triglyceride levels by 18% to 40% compared with a 2.9% increase with placebo (P≤0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: